Significance of thrombocytopenia in myelodysplastic syndromes: Associations and prognostic implications

Ali Al Ameri, Elias Jabbour, Guillermo Garcia-Manero, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Jianqin Shan, Sherry Pierce, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Purpose: To analyze the incidence and significance of thrombocytopenia in patients with myelodysplastic syndrome (MDS). Patients and Methods: A total of 2517 patients with MDS referred to our institution since 1993 were analyzed, with a specific focus on the incidence and associations of thrombocytopenia. Results: The median age of the study group was 66 years. The median survival was 13 months. Platelet counts <100 × 109/L were noted in 65%, and platelets counts <30 × 109/L in 26%. Each platelets count drop below the range of 200 × 109/L has shown a larger magnitude change in terms of worsening effect on survival. Therefore, smaller ranges of platelet counts of <200 × 109/L were studied. Platelet cutoffs of 30, 50, and 200 × 109/L thus were identified to have significant associations with differences in survival. Significant thrombocytopenia was associated with poor performance, other cytopenias, adverse karyotype, and advanced MDS phases. Thrombocytopenia was associated with worse prognosis; it also was predicted for worse outcome within each of the International Prognostic Scoring System risk groups. Conclusion: Prognosis in MDS is directly associated with the severity of thrombocytopenia.

Original languageEnglish (US)
Pages (from-to)237-241
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume11
Issue number2
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Thrombocytopenia
Platelet Count
Survival
Incidence
Karyotype
Blood Platelets
Age Groups

Keywords

  • Myelodysplastic syndrome
  • outcome
  • Thrombocytopenia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Al Ameri, A., Jabbour, E., Garcia-Manero, G., O'Brien, S., Faderl, S., Ravandi, F., ... Kantarjian, H. (2011). Significance of thrombocytopenia in myelodysplastic syndromes: Associations and prognostic implications. Clinical Lymphoma, Myeloma and Leukemia, 11(2), 237-241. https://doi.org/10.1016/j.clml.2011.03.005

Significance of thrombocytopenia in myelodysplastic syndromes : Associations and prognostic implications. / Al Ameri, Ali; Jabbour, Elias; Garcia-Manero, Guillermo; O'Brien, Susan; Faderl, Stefan; Ravandi, Farhad; Shan, Jianqin; Pierce, Sherry; Cortes, Jorge; Kantarjian, Hagop.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, No. 2, 01.04.2011, p. 237-241.

Research output: Contribution to journalArticle

Al Ameri, A, Jabbour, E, Garcia-Manero, G, O'Brien, S, Faderl, S, Ravandi, F, Shan, J, Pierce, S, Cortes, J & Kantarjian, H 2011, 'Significance of thrombocytopenia in myelodysplastic syndromes: Associations and prognostic implications', Clinical Lymphoma, Myeloma and Leukemia, vol. 11, no. 2, pp. 237-241. https://doi.org/10.1016/j.clml.2011.03.005
Al Ameri, Ali ; Jabbour, Elias ; Garcia-Manero, Guillermo ; O'Brien, Susan ; Faderl, Stefan ; Ravandi, Farhad ; Shan, Jianqin ; Pierce, Sherry ; Cortes, Jorge ; Kantarjian, Hagop. / Significance of thrombocytopenia in myelodysplastic syndromes : Associations and prognostic implications. In: Clinical Lymphoma, Myeloma and Leukemia. 2011 ; Vol. 11, No. 2. pp. 237-241.
@article{00e47441e59d4bdfb082c8da2a3edaa7,
title = "Significance of thrombocytopenia in myelodysplastic syndromes: Associations and prognostic implications",
abstract = "Purpose: To analyze the incidence and significance of thrombocytopenia in patients with myelodysplastic syndrome (MDS). Patients and Methods: A total of 2517 patients with MDS referred to our institution since 1993 were analyzed, with a specific focus on the incidence and associations of thrombocytopenia. Results: The median age of the study group was 66 years. The median survival was 13 months. Platelet counts <100 × 109/L were noted in 65{\%}, and platelets counts <30 × 109/L in 26{\%}. Each platelets count drop below the range of 200 × 109/L has shown a larger magnitude change in terms of worsening effect on survival. Therefore, smaller ranges of platelet counts of <200 × 109/L were studied. Platelet cutoffs of 30, 50, and 200 × 109/L thus were identified to have significant associations with differences in survival. Significant thrombocytopenia was associated with poor performance, other cytopenias, adverse karyotype, and advanced MDS phases. Thrombocytopenia was associated with worse prognosis; it also was predicted for worse outcome within each of the International Prognostic Scoring System risk groups. Conclusion: Prognosis in MDS is directly associated with the severity of thrombocytopenia.",
keywords = "Myelodysplastic syndrome, outcome, Thrombocytopenia",
author = "{Al Ameri}, Ali and Elias Jabbour and Guillermo Garcia-Manero and Susan O'Brien and Stefan Faderl and Farhad Ravandi and Jianqin Shan and Sherry Pierce and Jorge Cortes and Hagop Kantarjian",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.clml.2011.03.005",
language = "English (US)",
volume = "11",
pages = "237--241",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Significance of thrombocytopenia in myelodysplastic syndromes

T2 - Associations and prognostic implications

AU - Al Ameri, Ali

AU - Jabbour, Elias

AU - Garcia-Manero, Guillermo

AU - O'Brien, Susan

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Shan, Jianqin

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose: To analyze the incidence and significance of thrombocytopenia in patients with myelodysplastic syndrome (MDS). Patients and Methods: A total of 2517 patients with MDS referred to our institution since 1993 were analyzed, with a specific focus on the incidence and associations of thrombocytopenia. Results: The median age of the study group was 66 years. The median survival was 13 months. Platelet counts <100 × 109/L were noted in 65%, and platelets counts <30 × 109/L in 26%. Each platelets count drop below the range of 200 × 109/L has shown a larger magnitude change in terms of worsening effect on survival. Therefore, smaller ranges of platelet counts of <200 × 109/L were studied. Platelet cutoffs of 30, 50, and 200 × 109/L thus were identified to have significant associations with differences in survival. Significant thrombocytopenia was associated with poor performance, other cytopenias, adverse karyotype, and advanced MDS phases. Thrombocytopenia was associated with worse prognosis; it also was predicted for worse outcome within each of the International Prognostic Scoring System risk groups. Conclusion: Prognosis in MDS is directly associated with the severity of thrombocytopenia.

AB - Purpose: To analyze the incidence and significance of thrombocytopenia in patients with myelodysplastic syndrome (MDS). Patients and Methods: A total of 2517 patients with MDS referred to our institution since 1993 were analyzed, with a specific focus on the incidence and associations of thrombocytopenia. Results: The median age of the study group was 66 years. The median survival was 13 months. Platelet counts <100 × 109/L were noted in 65%, and platelets counts <30 × 109/L in 26%. Each platelets count drop below the range of 200 × 109/L has shown a larger magnitude change in terms of worsening effect on survival. Therefore, smaller ranges of platelet counts of <200 × 109/L were studied. Platelet cutoffs of 30, 50, and 200 × 109/L thus were identified to have significant associations with differences in survival. Significant thrombocytopenia was associated with poor performance, other cytopenias, adverse karyotype, and advanced MDS phases. Thrombocytopenia was associated with worse prognosis; it also was predicted for worse outcome within each of the International Prognostic Scoring System risk groups. Conclusion: Prognosis in MDS is directly associated with the severity of thrombocytopenia.

KW - Myelodysplastic syndrome

KW - outcome

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=80052822000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052822000&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2011.03.005

DO - 10.1016/j.clml.2011.03.005

M3 - Article

C2 - 21575929

AN - SCOPUS:80052822000

VL - 11

SP - 237

EP - 241

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 2

ER -